在心力衰竭的管理中使用midodrine:一个系统的审查
Nicholas Pavic1, Shane Zhang2, Emilie Zhou1
1College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Internal medicine journal
|September 27, 2025
概括
米多德林可能有助于一些心力衰竭患者耐受药物治疗,但证据有限. 需要更多的研究来确认midodrine是否可以安全地改善心力衰竭的结果,减少射出分数 (HFrEF).
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 指南导向医学疗法 (GDMT) 改善了心力衰竭的结果,减少了喷射率 (HFrEF).
- 低血压通常会限制HFrEF患者的GDMT的上升标配.
- 一种血管收缩剂米多德林 (Midodrine) 正在研究其管理血压并实现GDMT优化的潜力.
研究的目的:
- 系统地审查 midodrine 在治疗 HFrEF 的安全性和有效性.
- 评估midodrine对GDMT耐受性和患者结局的影响.
主要方法:
- 注册了系统审查 (CRD42024594291) 并根据PRISMA指南进行.
- 在PubMed,Medline,EMBASE,Cochrane和SCOPUS数据库中进行了搜索.
- 主要结局包括GDMT耐受性,左心室喷射分数 (LVEF) 恢复,心力衰竭住院治疗和全因死亡率.
主要成果:
- 包括五项研究 (12,063名HFrEF患者);由于异质性,无法进行元分析.
- 两项研究表明,midodrine增加了GDMT的患病率,并改善了LVEF.
- 两项研究表明,米多林的使用与住院住院,ICU访问和死亡率的增加有关.
结论:
- 缺乏高质量的证据支持midodrine在HFrEF中增加GDMT标位.
- 目前关于改善GDMT耐受性和LVEF的证据来自观察性研究.
- 随机试验对于确定midodrine在HFrEF中促进GDMT的安全性和有效性至关重要.
相关概念视频
01:30Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
01:22Heart Failure Drugs: β-Blockers
771
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
771
01:22Heart Failure Drugs: Diuretics
807
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
807
01:25Mitral Regurgitation III: Medical Management
284
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
284
01:28Mitral Regurgitation IV: Nursing Management
309
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
309